Guardant Health (GH) EBITDA Margin (2017 - 2025)
Historic EBITDA Margin for Guardant Health (GH) over the last 9 years, with Q3 2025 value amounting to 37.33%.
- Guardant Health's EBITDA Margin rose 239500.0% to 37.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 49.02%, marking a year-over-year increase of 254000.0%. This contributed to the annual value of 60.02% for FY2024, which is 401100.0% up from last year.
- Latest data reveals that Guardant Health reported EBITDA Margin of 37.33% as of Q3 2025, which was up 239500.0% from 45.85% recorded in Q2 2025.
- Over the past 5 years, Guardant Health's EBITDA Margin peaked at 37.33% during Q3 2025, and registered a low of 137.12% during Q1 2021.
- For the 5-year period, Guardant Health's EBITDA Margin averaged around 89.93%, with its median value being 90.84% (2021).
- As far as peak fluctuations go, Guardant Health's EBITDA Margin crashed by -854000bps in 2021, and later skyrocketed by 649700bps in 2024.
- Guardant Health's EBITDA Margin (Quarter) stood at 90.84% in 2021, then fell by -27bps to 115.15% in 2022, then fell by -11bps to 127.38% in 2023, then surged by 51bps to 62.42% in 2024, then surged by 40bps to 37.33% in 2025.
- Its EBITDA Margin stands at 37.33% for Q3 2025, versus 45.85% for Q2 2025 and 54.57% for Q1 2025.